meta
|
evidence
oncology
Living systematic review and meta-analysis
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
2
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
5
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
durvalumab based treatment
durvalumab plus etoposide and platin
pembrolizumab based treatment
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs etoposide plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Age < 65y (younger)
Age > 65y
Age > 75y (older)
Asian type
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (brain) NO
metastasis (brain) YES
metastasis (liver )
PDL1 (CPS < 1)
PDL1 (CPS >1)
smoker (current or former)
smoker (Current)
smoker (Former)
smoker (never)
stage III (locally advanced)
stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
DOR (extension)
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
SAE (grade 3-4)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthritis TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Guillain-Barré syndrome TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Nervous system disorders TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pancytopenia TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Peripheral sensory neuropathy TRAE (grade 3-4)
Pneumonia TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Hyperthyroidism AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increased Lipase Level AE (grade 3-4)
Leucopenia AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pneumonia AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
deaths (OS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
versus etoposide plus platin
durvalumab plus etoposide and platin vs. etoposide plus platin
1
0.73
[0.59; 0.91], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
durvalumab plus tremelimumab plus SoC vs. etoposide plus platin
1
0.82
[0.68; 0.99], 1 RCT, I2=0%
unassessable degree of certainty
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
0.70
[0.54; 0.91], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
ipilimumab plus SoC vs. placebo plus SoC
1
0.94
[0.81; 1.09], 1 RCT, I2=0%
inconclusive result
pembrolizumab plus SoC vs. placebo plus SoC
1
0.80
[0.65; 0.99], 1 RCT, I2=0%
unassessable degree of certainty
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open